Medication info

Linadia Duo Tablet 2.5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Dongguk Pharmaceutical Co., Ltd.
Appearance
Bright pink, double convex, oval film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201903155 · Approved 2019.05.15

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients who cannot achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching to this medicine from combination therapy with linagliptin and metformin should start at their current doses of linagliptin and metformin. 4. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients who cannot achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment due to its metformin component (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine).

Ingredients

Manufacturer
Dongguk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes who need to take linagliptin and metformin together to control blood sugar levels. Additionally, it works more effectively when used in conjunction with dietary and exercise regimens. Taking this medication regularly can aid in improving blood sugar management.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients who cannot achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching to this medicine from combination therapy with linagliptin and metformin should start at their current doses of linagliptin and metformin. 4. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients who cannot achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment due to its metformin component (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine).

Precautions

This medication can cause a rare but serious side effect called lactic acidosis and should not be used in patients with impaired kidney function or problems with heart or liver function. People who are allergic to this drug's active ingredient or components, patients with type 1 diabetes, acute myocardial infarction, or congestive heart failure, as well as pregnant or breastfeeding women should not take this medication. There is a risk of hypoglycemia, so blood sugar should be closely monitored when used with insulin or sulfonylureas, and dosages should be adjusted as necessary. Elderly patients with impaired kidney function or specific medical conditions should undergo regular kidney function tests, and treatment should be discontinued or adjusted if kidney function deteriorates. This medication should be temporarily discontinued during acute infections, dehydration, severe trauma, pre- and post-surgery, or during the use of radiocontrast agents, and treatment should be resumed once the condition stabilizes. This drug can cause side effects such as pancreatitis and skin disorders like bullous pemphigoid; therefore, if you experience persistent abdominal pain or blisters on the skin, you should notify your doctor immediately. While taking this medication, side effects such as gastrointestinal disturbances, taste disorders, fatigue, headaches, rashes, and hypoglycemia may occur, so if any abnormal symptoms arise, consult with a healthcare professional. Women planning a pregnancy or who are pregnant should not take this medication and should choose other safe methods for blood sugar control. This medication is not recommended for children under 10 years old or teenagers, and elderly patients may need dosage adjustments based on kidney function. It is advisable to avoid alcohol as it may increase the risk of lactic acidosis, and check with your doctor or pharmacist if you are taking other medications that may interact with this drug. When taking this medication, keep it out of reach of children and store it in a dry place. In case of overdose, remove the drug from the gastrointestinal tract, and if necessary, treatments like dialysis may be required, so visit a medical institution immediately.

Side effects

Lactic acidosis, rhinitis, hypersensitivity, angioedema, urticaria, vitamin B12 decrease and deficiency, hypoglycemia, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular bullous pemphigoid, severe and disabling arthralgia, rhabdomyolysis, increased lipase, increased amylase, constipation, epigastric pain, enterocolitis, intestinal obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disorder, Alzheimer's dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, concussion, palpitations, dry eye, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, cholelithiasis, hearing loss, erectile dysfunction, thyroid nodules, anemia, headache, paraesthesia, postherpetic neuralgia, hemiparesis, syncope, drowsiness, chest discomfort, weakness, epistaxis, oropharyngeal pain, voice disorder, nasal bleeding, benign prostatic hyperplasia, anxiety, affective disorder, insomnia, depression, contusion, bone contusion, meniscus injury, bone fracture, hand fracture, laceration, confusional state, nocturia, dermatitis, hypertension, pruritus, angina, stomatitis, mediastinitis, vitreous hemorrhage, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, rectal bleeding, cheilitis, dental caries, enteritis, gastritis, tooth loss, hemorrhoids, lower abdominal pain, viral upper respiratory infection, periodontitis, influenza, soft tissue infection, folliculitis, burning mouth syndrome, irritable bowel syndrome, dysphagia, gastric ulcer, gingival bleeding, increased blood triglycerides, increased urinary albumin/creatinine ratio, decreased hemoglobin, increased blood potassium, increased blood creatinine, increased blood creatine phosphokinase, increased ALT, increased AST, male pattern baldness, hyperhidrosis, dermatitis, insomnia, depression, hypertension, dizziness, benign prostatic hyperplasia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is recommended to maintain a storage temperature at room temperature between 1 and 30 degrees Celsius. This will help preserve the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

Bright pink, double convex, oval film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.